Results 251 to 260 of about 269,130 (350)

Bacterial Dysbiosis Observed in the Terminal Ileum of Ulcerative Colitis. [PDF]

Inflamm Bowel Dis
Mar JS, Nguyen A, Scherl A, Wittke M, Doona M, Lamb CA, Keir ME.   +6 more
europepmc   +1 more source

Twenty cases of restorative proctocolectomy for ulcerative colitis of Asian patients: analysis of operative safety and functional outcomes in single institution experience

, 2007
Yong Ko, Nam Kyu Kim, Byung So Min, Kang Young Lee, Seung Hyuk Baik, Chang Hwan Cho, Sang Kil Lee, Jae Hee Chen, Won Ho Kim   +8 more
openalex   +2 more sources

Unusual endoscopic remission in an anti‐tumor necrosis factor refractory case of severe ulcerative colitis during upadacitinib therapy

JPGN Reports, EarlyView.
Carine A. Halaby, Charlotte F. Kim, Richard Kellermayer   +2 more
wiley   +1 more source

Characteristics, properties and limitations of per‐ or polyfluoroalkyl substances (PFASs) and fluoropolymers

Polymer International, EarlyView.
An overview and categorization of man‐made per‐ or polyfluoroalkyl substances (PFASs) including low‐molar‐mass and high‐molar‐mass fluorochemicals, and their international regulations is presented. Though certain PFASs are toxic, bioaccumulative and cross the human cellular membranes, others, such as fluoropolymers, are safe, reliable and involved in ...
Bruno Améduri
wiley   +1 more source

Gallstone burden and risk in Korean patients with ulcerative colitis. [PDF]

Intest Res
Jeon SR.
europepmc   +1 more source

Advancing Extracellular Vesicle Research: A Review of Systems Biology and Multiomics Perspectives

PROTEOMICS, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are membrane‐bound vesicles secreted by various cell types into the extracellular space and play a role in intercellular communication. Their molecular cargo varies depending on the cell of origin and its functional state.
Gloria Kemunto, Samaneh Ghadami, Kristen Dellinger   +2 more
wiley   +1 more source

Analysis of common differential gene expression between rheumatoid arthritis and ulcerative colitis. [PDF]

PLoS One
Han PF, Cui WR, He FZ, Wu T, Liao CS.
europepmc   +1 more source

Defensins and Efflux Transporters Meet Their Fate in 2008: No Major Role in the Pathogenesis of Inflammatory Bowel Disease [PDF]

, 2008
Ochsenkühn, Thomas
core   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source

Macrophages: emerging targets for ulcerative colitis. [PDF]

Front Immunol
Chen S, Qin Z, Lin X, Zhou S, Xu Y, Zhu Y.   +5 more
europepmc   +1 more source